Introduction
Definitive diagnosis of Alzheimer's disease (AD) and other age-related neurodegenerative diseases, including Lewy body disease (LBD), requires autopsy confirmation. The latest guidelines for the neuropathological diagnosis of AD and related diseases were devised by a group of international experts organised by the National Institute on Aging and the Alzheimer's Association (NIA-AA), and were published in 2012 as the NIA-AA guidelines for the pathological assessment of Alzheimer's disease and related disorders.
1, 2 The guidelines recommend sampling 20 separate brain regions using diverse histochemical and/or immunohistochemical stains to characterise AD pathology according to amyloid plaque 3 and neurofibrillary tangle 4 distribution, neuritic plaque density 5 and other disease processes, including cerebral amyloid angiopathy (CAA), LBD (distribution), microvascular brain injury (microinfarct burden) and hippocampal sclerosis. Neuropathologists in AD centres (ADCs) and other research settings have implemented the NIA-AA guidelines successfully, and the approach is effective for the diagnosis of a wide range of neurodegenerative disorders with a high specificity and sensitivity. 6 However, non-ADCaffiliated neuropathologists raised concerns that the approach had limited applicability due to its high cost burden, particularly in smaller academic or private practice and forensic pathology settings.
In response, our group designed the condensed protocol (CP) for the NIA-AA guidelines to enable application of the NIA-AA criteria in these settings. 7 The CP maintains sampling from 20 recommended regions in the NIA-AA guidelines while reducing the number of paraffin blocks and routine stains (from 20 to five, each), immunostains (from 13 to three) and cost (by~75%). The pooling of multiple samples into each block and the choice of the subsequent immunostain was designed strategically in such a way that maximum information regarding the severity and distribution of AD and LBD pathology could be obtained from a minimum number of blocks. We tested sensitivity and specificity of the CP in relation to the original (gold standard) NIA-AA guidelines retrospectively in 30 selected research autopsies and then prospectively in 20 consecutive research autopsies from the UW Neuropathology Core. We reported that CP maintained excellent specificity for lesions of AD, LBD and microvascular brain injury (lVBI) as assessed by microvascular lesions (MVLs), and maintained excellent sensitivity for AD neuropathological changes and moderate sensitivity for LBD. The CP had poor sensitivity for MVLs, as we had anticipated. 7 Alzheimer's disease neuropathological change is highly prevalent in elderly people, and is often accompanied by some degree of LBD and lVBI. Recognising that routine hospital autopsies are unlikely to undergo complete NIA-AA sampling and work-up, there may be some benefit over standard neuropathological practice to implement the CP in this setting to detect AD and LBD. We tested this by developing selection criteria relevant to a clinical autopsy practice to determine when to apply the CP protocol, and then implementing the selection process and CP during approximately 1 year to consecutive autopsies at the UW Medical Center (UWMC) in Seattle, Washington. Here we provide evidence for the feasibility of the CP in a large hospital-based autopsy service where, irrespective of clinical diagnosis, brain sections from each case aged 65 years or older underwent CP sampling and screening using standard haematoxylin and eosin (H&E) staining; if pathological features of neurodegeneration, such as amyloid plaques, neurofibrillary tangles, Lewy bodies or other neurodegenerative features, were identified on H&E, CP special stains were performed and complete CP examination undertaken.
Materials and methods

C A S E S E L E C T I O N
The use of human subject material was performed in accordance with the Declaration of Helsinki and the guidelines set by the UW Institutional Review Board, including a waiver of informed consent. The neuropathology faculty (P.J.C., L.G.-C., G.J.-S., D.A.M., C.D.K), in conjunction with neuropathology fellows (R.B., M.E.F., C.S.L.), perform complete neuropathological examinations at a weekly UWMC Braincutting Conference as part of the routine clinical autopsy service. Except in rare circumstances, the brain from every adult autopsy is examined at this conference.
In our original CP study, 7 every case in the retrospective and prospective cohorts underwent the CP sampling and staining protocol. However, for a routine neuropathology practice where clinical neurological information is uncommon and there is an absence of research quality psychometric and other data, we recognised the need for a screening method and criteria to determine which cases underwent the full CP work-up. Based on historical data from our institution, we recognised that age 65 or older, or clinical concern for dementia or neurodegenerative disease, represented inclusion criteria that would capture virtually all prior cases that underwent extensive neurodegenerative disease neuropathology work-up. The CP sampling protocol was instituted in cases that met either of these criteria. Briefly, in addition to the 10 blocks that we submitted for routine neuropathological examination of hospital autopsy cases, the 20 brain regions that were sampled in the detailed NIA-AA protocol were consolidated in five blocks exactly according to our published protocol. 7 However, unlike our original study, special stains were not performed before first examining H&E-stained sections from the five CP blocks (Figure 1) . If neurodegenerative pathology or changes suspicious for neurodegeneration were identified in any of the H&E-stained sections, such as amyloid (A) b plaques, neurofibrillary tangles, Lewy bodies, Hirano bodies, granulovacuolar degeneration, hippocampal sclerosis, frank cortical neurone loss or gliosis, etc., CP protocol special stains were ordered and evaluated according to NIA-AA guidelines. Tissue processing and H&E, immunohistochemical and Bielschowsky staining were performed according to standardised and validated protocols already established in the UW Department of Pathology.
Detailed and diagrammed sections are described by Flanagan et al. 7 Briefly, a section from a block containing cerebellar cortex, right caudate/internal capsule/putamen, right calcarine cortex and hemimidbrain with substantia nigra and peri-aqueductal grey was stained with an anti-Ab mouse monoclonal antibody (clone 6F/3D; 1:10 dilution; Dako/Agilent, Santa Clara, CA, USA) to detect Ab plaque distribution for Thal phase (A score). A section from a block containing right hippocampus (including entorhinal and transentorhinal cortex), right superior frontal gyrus, right superior temporal gyrus and left calcarine cortex was immunostained with an anti-tau mouse monoclonal antibody (clone Tau- 
Results
Postmortem brains from 73 cases from the general autopsy service were examined by the condensed NIA-AA protocol ( Figure 1 , Table 1 ). The age range was 59-94 years with a mean age of 73 years. The only patient aged below 65 years in this series had a clinical history of dementia, and was therefore included for CP. In this series, a majority (n = 47; 64%) of the patients were men. Most of the cases (n = 64; 88%) did not have formal neurological evaluations, but a subset of decedents was diagnosed with either dementia (n = 3), mild cognitive impairment (n = 2), cognitive decline not otherwise specified (n = 2) or movement disorder (n = 2). Of the 73 CP cases evaluated, 73% (n = 53) showed histopathological features suspicious for neurodegeneration on H&E staining (Figure 1 ). These features included neurofibrillary tangles, extracellular plaques, Lewy bodies, Hirano bodies, granulovacuolar degeneration or substantial cortical/hippocampal neurone loss/gliosis. These cases were examined further by immunostaining with the antibodies described above and Bielschowsky staining according to the recently published protocol. 7 Sections of the brain exhibited various neurodegenerative changes, including neurofibrillary tangles (labelled by p-Tau antibody), neuritic plaques (labelled by p-Tau antibody and Bielschowsky stain) and Lewy bodies (highlighted by a-synuclein antibody). Representative photomicrographs of these histological structures are shown in Figure 2 . AD pathology was graded according to the 2012 NIA-AA consensus recommendations, integrating Thal, Braak and CERAD scores using an ABC scoring system. These cases demonstrated various degrees of AD pathological change, including high AD pathology in 5% (n = 4) of cases, intermediate AD pathology in 15% (n = 11) and low AD pathology in 10% (n = 7) of cases ( Table 2) . Of the three cases with a clinical diagnosis of dementia, one was a 94-year-old patient diagnosed pathologically with neurofibrillary tangle only dementia, one was an 80-year-old patient with high AD neuropathological change and one was a 59-year-old patient with mixed pathology including brain stem-predominant LBD, hippocampal sclerosis, vascular brain injury and primary age-related tauopathy (PART). Among the two cases described clinically as having mild cognitive impairment (MCI), one was a 68-year-old patient with intermediate AD neuropathological change and the other was an 89-year-old patient with mixed pathologies, including high AD neuropathological change, cerebral amyloid angiopathy (CAA) and neocortical (diffuse) LBD.
Neurodegenerative findings outside AD neuropathological changes were observed frequently ( Table 2) . CAA was present in 15% (n = 11) of cases as assessed by the presence of Ab in cerebral vasculature. PART was diagnosed in 21% (n = 15) of cases, while LBD was present in 15% (n = 11) cases. The distribution of LB was brain stem-predominant (n = 6), limbic (transitional) (n = 2), neocortical (diffuse) (n = 1) and amygdala-predominant (n = 2) ( Table 2 ). There were two cases with a clinical diagnosis of a movement disorder, including a 77-yearold patient found to have intermediate AD changes and CAA (further extensive sampling and immunohistochemical work-up outside CP excluded additional aetiologies including non-AD tauopathy) and an 84-year-old patient with brain stem-predominant LBD with intermediate AD changes. Overall, mixed neuropathological processes (as defined by at least two comorbid listed pathological diagnoses) occurred in 19% (n = 14) of the cases examined with the full CP. 
Discussion
The CP for the NIA-AA guidelines for the pathological assessment of Alzheimer's and other neurodegenerative diseases was developed to reduce time and resources necessary to perform the recommended neuropathological assessment. The CP was envisioned for hospital and forensic autopsy practices that lack resources to perform the full NIA-AA work-up, so we implemented the CP for neuropathology examinations of cases from an academic medical centre (UWMC and affiliated hospitals) in our clinical practice. Recognising the need for selection criteria to identify cases to undergo CP sampling and work-up, we devised a stepwise CP implementation scheme in which decedents aged ≥65 or with a clinical suspicion for neurodegenerative disease underwent CP sampling and screening for neurodegenerative pathology on H&E slides; when neurodegenerative disease neuropathology was identified, three immunostains (Ab, p-Tau and a-synuclein) and a Bielschowsky silver stain were performed. We chose H&E screening to replicate our existing practice in which neurodegenerative disease work-up was triggered with H&E pathology and to further control time and resource requirements.
The CP was not intended for, and does not perform as, a comprehensive replacement for the NIA-AA Guidelines for the neuropathological assessment of AD and related pathologies. However, this study confirms that the CP may be a reasonable alternative approach to assess AD neuropathological change and LBD when resources are limited. We chose age 65 as a threshold to perform CP sampling reflexively, but we recognise that limiting the CP to cases with suspected dementia or neurological disease irrespective of age to control resources further may be more practical in some settings. Indeed, the CP enabled identification of neuropathological changes sufficient to explain clinical dementia or cognitive impairment in all our cases.
As a cost-effective measure for AD work-up in the non-research setting, we have shown previously that the CP saves approximately $901.27 (78%) per case compared to the full NIA-AA work-up. 7 While the cost savings per case are evident, two confounds preclude the cost comparison for UW cases undergoing work-up before and after implementation of our CP sampling protocol. First, the algorithm to include all cases age ≥65 was initiated arbitrarily for application of the CP in clinical practice and resulting CP sampling (in addition to routine blocks) almost certainly triggering a lower threshold for immunostaining. Secondly, of the five practising neuropathology faculty members at UW participating in the CP, only two were in practice at UW for more than 1 year before implementation of the CP. Therefore, individual preferences and practices may have changed as faculty members were added. Besides the cost-effectiveness, an unexpected positive consequence of application of the CP in our clinical practice was increased consistency of sampling and examination of cases and increased awareness by faculty and trainees, in general, regarding neuropathology of neurodegeneration. Our study provides the first test of the utility of the condensed NIA-AA protocol outside the research setting, in a hospital-based general autopsy service. Our approach identified neurodegenerative changes in a large proportion of cases above what we recognised with previous, targeted assessments. We provided a comparison of the sensitivity and specificity between NIA-AA Guidelines and the CP in our original paper, 7 where we concluded that neuropathological analysis using the CP reduces the cost of analysis by 75% relative to the NIA-AA Guidelines without significant compromise in diagnostic sensitivity and specificity for AD and LBD. The specificity of the CP for all lesion types was above 85%, whereas the sensitivity was variable for different lesions. For AD pathology, the sensitivity was >80%. For LBD, the sensitivity was <60% for ranked evaluations (<60%) but increased to 80% using 'any' versus 'none' criteria. In the absence of a direct comparison with full and condensed protocols in the current patient population, the sensitivity and specificity of the CP for AD and LBD may be different from the original study in a research autopsy cohort. Thus, use of the CP has limitations compared with the NIA-AA Guidelines, but still provides an alternative that we have shown is feasible for the evaluation of AD, LBD and hippocampal sclerosis in clinical or forensic practice in cases above a certain age or with suspected neurodegenerative disease.
We recognise that Bielschowsky stains are expensive and not available to many laboratories. Silver stains are included in the CP as a convenient method to detect neuritic plaques and neurofibrillary tangles in the same tissues, but silver stains are not required in the full NIA-AA guidelines. Indeed, the p-Tau block in the CP was designed to be sufficient to assess neurofibrillary degeneration according to the full NIA-AA guidelines and supported by studies by Braak et al.
8 using p-Tau immunohistochemistry. Calcarine cortex was chosen in our original CP study 7 as the cerebral cortex sample in the Ab immunohistochemistry block in order to combine assessments for the presence of diffuse amyloid plaques and cerebral amyloid angiopathy (CAA). We recognised that occipital cortex was optional for the full NIA-AA assessment, but Thal et al. 3 reported Ab deposits in occipital cortex, in addition to frontal, parietal and temporal cortex, in Phase I. Further, guidelines for the assessment of CAA either include occipital cortex 9 or direct the assessment specifically to occipital cortex 10 for sampling to assess contributions of cerebrovascular pathology to cognitive impairment. The Bielschowsky silver stain can be used to detect diffuse plaques (albeit with less sensitivity than IHC), and silver and paired helical filament (PHF)-tau stains can be used to detect neuritic plaques.
We have reported previously that the most significant limitation of the CP lies in its poor sensitivity for the detection of microvascular lesions. 7 These lesions are not grossly identifiable and are infrequent even in severe cases; thus, random detection of these lesions is highly dependent upon the amount of tissue sampled. In addition to the five blocks submitted for the CP, we examine 10 standard sections of brain (including bilateral basal ganglia) routinely for each case using H&E staining. However, in cases with a strong suspicion for MVL, if the above-mentioned approach does not identify a MVL, or in cases of suspected dementia in which pathological changes sufficient to explain the clinical symptoms are not identified with the CP, more extensive sampling of 
NFT only dementia
Hippocampal sclerosis n = 1 (1%)
Cases with ≥2 pathologies n = 14 (19%) AD, Alzheimer disease; CAA, Cerebral amyloid angiopathy; PART, Primary age-related tauopathy; LBD, Lewy body disease; NFT, Neurofibrillary tangle.
brain areas can be performed for H&E stains at low cost. Microvascular brain injury is an important contributor to dementia; we have designed, but not tested, supplementary sampling to align more effectively with NIA-AA guidelines to detect MVLs, but these protocols are untested. Modifications to CP beyond additional sampling may be needed to address this important issue in research and academic/community/forensic settings. Similar to microvascular brain injury, reduced sampling area increases the probability that pathological features will be missed in low burden Ab cases. However, any sampling protocol, including the full NIA-AA guidelines, is susceptible to sampling error depending on the frequency of the pathological feature in question. Additional studies are needed to determine thresholds for false negatives in the full and condensed NIA-AA protocols to determine sensitivities for each pathological feature in comparison with the other across a wide range of pathological burden, but in the original CP study we did not see a significant reduction in sensitivity of detection of amyloid pathology compared with NIA-AA protocols.
We recognise that the CP is not designed for diagnosis of other less common forms of neurodegenerative disease including frontotemporal lobar degeneration, chronic traumatic encephalopathy (CTE), Huntington's disease, amyotrophic lateral sclerosis, Niemann-Pick, corticobasal degeneration or progressive supranuclear palsy, etc. However, apart from CTE, these entities are so rare that savings from applying the CP would not justify application of the CP over usual diagnostic protocols. The CP, like the original NIA-AA guidelines, is not designed as a comprehensive assessment tool for diverse neurodegenerative diseases, but is designed as a first step to assess common (AD, LBD) neurodegenerative pathologies in association with cognitive impairment/dementia.
There has been marked variability in the approach towards neuropathological diagnosis of AD among different clinical practices. Our study presents a standardised approach for examination of neurodegenerative pathology that is pathologist-independent and has already been validated to have a high level of agreement between pathologists. 6 In every case with an established clinical diagnosis of dementia, mild cognitive impairment or movement disorder, neuropathological changes sufficient to explain the clinical presentation were identified with the CP. In addition, we identified AD-related and other pathologies in several cases with no established diagnosis of dementia, cognitive impairment or other neurological condition. Extensive clinicopathological correlation in these cases could not be performed due to the lack of detailed motor and cognitive examination/testing in these patients.
In addition to providing relevant clinical information for decedents' families, the use of condensed NIA-AA protocol for general autopsy service also provides relevant information regarding the prevalence of AD pathology in an academic medical centre population. Approximately 20% of cases examined in this study were diagnosed with intermediate to high AD pathology. Multiple studies have documented the presence of significant AD neuropathological changes in the absence of cognitive impairment. Elobeid et al. 11 reported, in a hospitalbased study of non-demented patients, that 15% showed intermediate AD pathology according to the 2012 NIA-AA criteria. 11 Bennett et al. 12 performed a large-scale study in which they examined the prevalence of AD pathology in 134 subjects without dementia using the NIH-Reagan criteria. Approximately 1.5% of the cases had a high likelihood of AD and 35.8% had an intermediate likelihood of AD.
12 Similar results were obtained by Cholerton et al., 13 who found a high number of cases with moderate neuritic plaques and Braak scores of III-VI in cases without clinical dementia. 13 Our study presents the first example, to our knowledge, for the use of the condensed NIA-AA protocol in a hospitalbased population and lays the foundation for more sophisticated studies in future.
